Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1586057

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1586057

Cancer Therapeutics & Supportive Care Drugs Market by Cancer Type (Breast Cancer, Lung Cancer, Melanoma), Drug Class (Antiemetics, Bisphosphonates, Erythropoietin-Stimulating Agents) - Global Forecast 2025-2030

PUBLISHED:
PAGES: 197 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Cancer Therapeutics & Supportive Care Drugs Market was valued at USD 302.65 billion in 2023, expected to reach USD 334.30 billion in 2024, and is projected to grow at a CAGR of 10.54%, to USD 610.72 billion by 2030.

The scope and definition of the cancer therapeutics and supportive care drugs market encompass a range of pharmaceutical products and therapies designed to treat cancer or alleviate the symptoms and side effects of cancer treatment. This market includes traditional cytotoxic drugs, targeted therapies, immunotherapies, and supportive care drugs like antiemetics and pain relievers. The necessity for these drugs stems from the increasing prevalence of various types of cancer globally and the need for comprehensive treatment options that not only target cancer cells but also mitigate the adverse effects of treatment protocols. The application and end-use scope of these drugs involves hospitals, cancer treatment centers, research institutes, and individual patients benefitting from home-based care solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 302.65 billion
Estimated Year [2024] USD 334.30 billion
Forecast Year [2030] USD 610.72 billion
CAGR (%) 10.54%

Key factors influencing market growth include the rising incidence of cancer, advancements in biotechnology facilitating the development of personalized medicine, and increased healthcare spending globally. Potential opportunities lie in emerging markets, innovative drug formulations, and combination therapies that promise enhanced efficacy and reduced side effects. To capitalize on these opportunities, stakeholders should invest in R&D, foster collaborations for drug development, and focus on personalized and precision medicine approaches.

However, market growth is challenged by high costs associated with drug development and cancer treatment, regulatory hurdles, and the adverse effects of some cancer drugs, leading to patient compliance issues. Innovations in this sector could focus on improving drug delivery systems, discovering new biomarkers for earlier diagnosis and targeted treatment, and developing cost-effective and scalable production methods for complex biologics. The market is dynamic, characterized by rapid technological advancements and fierce competition among key players; thus, sustained growth necessitates continued investment in innovation, regulatory understanding, and strategic alliances. To navigate challenges, it is essential for businesses to remain agile, responsive to market changes, and committed to patient-centered product development.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Therapeutics & Supportive Care Drugs Market

The Cancer Therapeutics & Supportive Care Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer patients
    • Innovations in the development of new drugs and therapies
    • Growing demand for non-invasive therapies
  • Market Restraints
    • High cost of cancer drugs
  • Market Opportunities
    • Ongoing innovations for the treatment of cancer
    • Clinical trials and developments of biosimilars and biologics
  • Market Challenges
    • Limited reimbursement options

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Therapeutics & Supportive Care Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Therapeutics & Supportive Care Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Therapeutics & Supportive Care Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Therapeutics & Supportive Care Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Therapeutics & Supportive Care Drugs Market

A detailed market share analysis in the Cancer Therapeutics & Supportive Care Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Therapeutics & Supportive Care Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Therapeutics & Supportive Care Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Therapeutics & Supportive Care Drugs Market

A strategic analysis of the Cancer Therapeutics & Supportive Care Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Therapeutics & Supportive Care Drugs Market, highlighting leading vendors and their innovative profiles. These include Acacia Pharma Group PLC, Amgen Inc., Aphios Corporation, AstraZeneca PLC, Bayer AG, Celldex Therapeutics, GSK PLC, Helsinn Healthcare SA, Heron Pharma, Ipsen Pharma, Johnson & Johnson, Merck & Co., Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Therapeutics & Supportive Care Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cancer Type, market is studied across Breast Cancer, Lung Cancer, Melanoma, and Prostate Cancer.
  • Based on Drug Class, market is studied across Antiemetics, Bisphosphonates, Erythropoietin-Stimulating Agents, Granulocyte-Colony Stimulating Factors, Nonsteroidal Anti-Inflammatory Drugs, and Opioids.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-4316E4E89554

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer patients
      • 5.1.1.2. Innovations in the development of new drugs and therapies
      • 5.1.1.3. Growing demand for non-invasive therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing innovations for the treatment of cancer
      • 5.1.3.2. Clinical trials and developments of biosimilars and biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Limited reimbursement options
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Therapeutics & Supportive Care Drugs Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Breast Cancer
  • 6.3. Lung Cancer
  • 6.4. Melanoma
  • 6.5. Prostate Cancer

7. Cancer Therapeutics & Supportive Care Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Antiemetics
  • 7.3. Bisphosphonates
  • 7.4. Erythropoietin-Stimulating Agents
  • 7.5. Granulocyte-Colony Stimulating Factors
  • 7.6. Nonsteroidal Anti-Inflammatory Drugs
  • 7.7. Opioids

8. Americas Cancer Therapeutics & Supportive Care Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cancer Therapeutics & Supportive Care Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cancer Therapeutics & Supportive Care Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acacia Pharma Group PLC
  • 2. Amgen Inc.
  • 3. Aphios Corporation
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Celldex Therapeutics
  • 7. GSK PLC
  • 8. Helsinn Healthcare SA
  • 9. Heron Pharma
  • 10. Ipsen Pharma
  • 11. Johnson & Johnson
  • 12. Merck & Co.
  • 13. Novartis International AG
  • 14. Sanofi SA
  • 15. Sun Pharmaceutical Industries Ltd.
  • 16. Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4316E4E89554

LIST OF FIGURES

  • FIGURE 1. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIETIN-STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AUSTRALIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. INDIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. INDONESIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. JAPAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MALAYSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. PHILIPPINES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. SINGAPORE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. SOUTH KOREA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. TAIWAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. THAILAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. VIETNAM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. DENMARK CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. EGYPT CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. FINLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ISRAEL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NETHERLANDS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NIGERIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. NORWAY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. POLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. QATAR CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SAUDI ARABIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SWEDEN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. SWITZERLAND CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. TURKEY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED ARAB EMIRATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 106. CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!